TXG 10x Genomics Inc

Price (delayed)

$49.63

Market cap

$5.63B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.8

Enterprise value

$5.41B

10x Genomics is an American biotechnology company that designs and manufactures gene sequencing technology used in scientific research. It was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin ...

Highlights
The company's gross profit has surged by 53% YoY
10x Genomics's revenue has soared by 50% YoY
TXG's EPS has soared by 85% year-on-year but it has dropped by 51% since the previous quarter
The company's net income has surged by 83% YoY but it has shrunk by 53% QoQ
10x Genomics's debt has increased by 40% YoY and by 23% QoQ

Key stats

What are the main financial stats of TXG
Market
Shares outstanding
113.37M
Market cap
$5.63B
Enterprise value
$5.41B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.94
Price to sales (P/S)
11.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.83
Earnings
Revenue
$499.17M
EBIT
-$83.52M
EBITDA
-$53.76M
Free cash flow
-$128.64M
Per share
EPS
-$0.8
Free cash flow per share
-$1.14
Book value per share
$7.15
Revenue per share
$4.42
TBVPS
$8.62
Balance sheet
Total assets
$1B
Total liabilities
$196.57M
Debt
$101.18M
Equity
$806.69M
Working capital
$602.89M
Liquidity
Debt to equity
0.13
Current ratio
7.38
Quick ratio
6.6
Net debt/EBITDA
4.07
Margins
EBITDA margin
-10.8%
Gross margin
83.5%
Net margin
-17.8%
Operating margin
-16.8%
Efficiency
Return on assets
-8.9%
Return on equity
-11.1%
Return on invested capital
-20.1%
Return on capital employed
-9.2%
Return on sales
-16.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TXG stock price

How has the 10x Genomics stock price performed over time
Intraday
6.8%
1 week
29.24%
1 month
8.55%
1 year
-74.43%
YTD
-66.68%
QTD
-34.76%

Financial performance

How have 10x Genomics's revenue and profit performed over time
Revenue
$499.17M
Gross profit
$416.66M
Operating income
-$83.77M
Net income
-$89.09M
Gross margin
83.5%
Net margin
-17.8%
10x Genomics's operating margin has surged by 89% YoY but it has shrunk by 57% QoQ
10x Genomics's net margin has surged by 89% YoY but it has decreased by 50% QoQ
TXG's operating income has surged by 84% year-on-year but it has dropped by 60% since the previous quarter
The company's net income has surged by 83% YoY but it has shrunk by 53% QoQ

Growth

What is 10x Genomics's growth rate over time

Valuation

What is 10x Genomics stock price valuation
P/E
N/A
P/B
6.94
P/S
11.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10.83
TXG's EPS has soared by 85% year-on-year but it has dropped by 51% since the previous quarter
The P/B is 65% below the last 4 quarters average of 19.6
TXG's equity is up by 7% year-on-year
The stock's price to sales (P/S) is 68% less than its last 4 quarters average of 34.7
10x Genomics's revenue has soared by 50% YoY

Efficiency

How efficient is 10x Genomics business performance
The return on invested capital has surged by 94% year-on-year but it has declined by 20% since the previous quarter
TXG's ROS has soared by 89% year-on-year but it has dropped by 55% since the previous quarter
The ROE has soared by 86% YoY but it has plunged by 50% from the previous quarter
TXG's ROA has soared by 85% YoY but it has plunged by 51% from the previous quarter

Dividends

What is TXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TXG.

Financial health

How did 10x Genomics financials performed over time
The current ratio has grown by 19% YoY and by 9% from the previous quarter
The company's quick ratio rose by 13% YoY and by 7% QoQ
10x Genomics's debt is 87% lower than its equity
10x Genomics's debt has increased by 40% YoY and by 23% QoQ
10x Genomics's debt to equity has increased by 30% QoQ and by 30% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.